Next-generation proteasome blockers promise safer cancer therapy.
Asher
A
Mullard
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001896:Boron Compounds / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015853:Cysteine Proteinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval / Q000191:economics*; D004345:Drug Industry / Q000191:economics*; D005998:Glycine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use; D061988:Proteasome Inhibitors
D000970:Antineoplastic Agents; D001896:Boron Compounds; D015853:Cysteine Proteinase Inhibitors; D009842:Oligopeptides; D061988:Proteasome Inhibitors; C548400:ixazomib; C524865:carfilzomib; D005998:Glycine